Cigna (CI) Stock Tumbles Despite Strong Q1 Earnings Beat and Raised Guidance

TLDR

• Q1 adjusted earnings per share reached $7.79, surpassing analyst expectations of $7.60
• Quarterly revenue increased 5% to $68.5 billion, exceeding the $66.3 billion forecast
• Company elevated 2026 full-year EPS outlook to a minimum of $30.35, representing a $0.10 increase
• Shares declined approximately 3% despite positive results, with pharmacy benefits division cited as concern
• David Cordani stepping down as CEO on July 1; Brian Evanko, current COO, will assume leadership role

Cigna delivered an impressive first-quarter performance, yet investors responded with skepticism. The healthcare giant exceeded expectations on both the top and bottom lines and increased its annual forecast, but shares still tumbled in trading.

Adjusted earnings per share for the quarter totaled $7.79, representing growth from $6.74 in the prior-year period and surpassing the Street’s $7.60 projection. Total revenue reached $68.5 billion, marking a 5% year-over-year climb and beating the anticipated $66.3 billion.

Management also revised upward its 2026 full-year EPS projection to at least $30.35, representing a $0.10 bump from the company’s earlier guidance. This midpoint slightly exceeds the analyst consensus estimate of $30.33.

Cigna Corporation, CI

Yet the positive results didn’t translate to market gains, with shares declining roughly 3% to approximately $283 during morning trading hours.

Operational adjusted income climbed 12% to reach $2.1 billion, up from $1.8 billion in the first quarter of 2025. The performance improvement stemmed primarily from contributions by Cigna Healthcare and Evernorth Health Services divisions.

The Cigna Healthcare segment saw pre-tax adjusted operational income surge 18% to $1.5 billion. The division’s medical care ratio showed improvement, falling to 79.8% from the previous year’s 82.2%.

Evernorth posted adjusted revenues totaling $58.4 billion, representing 9% year-over-year growth. The Specialty and Care Services segment delivered particularly strong results, with income advancing 20% to $1.1 billion.

Pharmacy Business Under the Microscope

The problematic area centered on the pharmacy benefit manager operations. TD Cowen analyst Charles Rhyee characterized it as the “only blemish” in an otherwise solid quarterly report, though he emphasized the weakness wasn’t unexpected given comparable challenges at UnitedHealth and Elevance Health. Rhyee maintained his Buy recommendation with a $338 target price.

Since autumn, Cigna has been restructuring its PBM operations, transitioning toward a “rebate-free” framework in response to mounting regulatory scrutiny and public backlash regarding pharmaceutical pricing mechanisms.

Leadership Transition Adds Uncertainty

This past February, Cigna’s Express Scripts division became the initial major PBM to reach a settlement agreement with the Federal Trade Commission concerning insulin pricing litigation. The company denied any wrongdoing, and the settlement terms corresponded with the previously announced rebate-free business model.

The organization is simultaneously navigating a significant leadership transition. Current CEO David Cordani plans to retire effective July 1, with Chief Operating Officer Brian Evanko designated as his successor.

The convergence of operational model transformation, executive leadership transition, and measured analyst sentiment provides context for why strong quarterly results and elevated guidance failed to generate positive stock momentum.

The quarter’s most encouraging indicators included the enhanced medical care ratio and robust organic expansion within specialty business segments.

The post Cigna (CI) Stock Tumbles Despite Strong Q1 Earnings Beat and Raised Guidance appeared first on Blockonomi.